Edition:
United Kingdom

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.90USD
23 May 2018
Change (% chg)

$0.01 (+0.53%)
Prev Close
$1.89
Open
$1.89
Day's High
$1.94
Day's Low
$1.88
Volume
60,719
Avg. Vol
154,610
52-wk High
$2.55
52-wk Low
$0.75

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $305.63
Shares Outstanding(Mil.): 161.71
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.03 -- --
ROI: -10.48 -7.38 12.74
ROE: -23.05 -10.11 14.64

BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz

* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)

09 May 2018

BRIEF-Durect Corporation Q1 Loss Per Share $0.05

* DURECT CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

02 May 2018

BRIEF-Durect Announces FDA Advisory Committee Meeting For Remoxy Er

* DURECT ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER

20 Mar 2018

BRIEF-Durect Corporation Qtrly Earnings Per Share ‍$0.05​

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS

01 Mar 2018

BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928

* DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING

26 Feb 2018

Earnings vs. Estimates